Abstract
[Purpose] Antiemetic therapy, used for chemotherapy-induced nausea and vomiting (CINV), is important in deciding whether to continue or terminate treatment, and improving the QOL of patients. In this study, we compared the antiemetic effect of the new fosaprepitant (Proemend®) with that of the conventional aprepitant (Emend®) in oral cancer patients treated with cisplatin. [Subjects and Methods] Fifteen patients who had progressive squamous cell carcinoma and were being treated with cisplatin (over 60mg/m2) chemotherapy between April 2010 and December 2012 at our Center were enrolled in the study. The evaluation of digestive symptoms was categorized following the “Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0” and “Proemend Specific Use Survey”. The presence or absence of CINV in acute and delayed phases was compared. [Result] In the acute phase, 100% of the patients in the fosaprepitant group did not vomit and 80% in the aprepitant group; 100% of the patients in the fosaprepitant group did not show nausea and 40% in the aprepitant group; thus, there was a significant difference (p = 0.022) in nausea in the acute phase. In the delayed phase, 90% of the patients in the fosaprepitant group did not vomit and 100% in the aprepitant group; 50% of the patients in the fosaprepitant group did not show nausea and 0% in the aprepitant group. [Conclusion] Although it could not be controlled with aprepitant, fosaprepitant is considered to be useful Because the occurrence of nausea and vomiting caused by cisplatin decreased with the application of fosaprepitant.
